World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models TAICHUNG, Feb. 13, 2026 /PRNewswire/ — Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell therapy. China Medical University Hospital (CMUH) announced today that, in collaboration with Ever Supreme Bio Technology, it has successfully developed the world’s first EXO 001 targeted exosome platform, a breakthrough technology that enables direct in vivo programming of T cells […]

World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors #CancerResearch #CAR_Therapy #ExosomeTechnology #SolidTumors #MedicalInnovation

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and al...

🧠 Scientists engineered CAR-T cells to attack Alzheimer’s plaques in mice, showing promise for a new type of therapy. Game-changer or just a first step?

www.news-medical.net/news/2026021... #Alzheimers #CAR_Therapy #NeuroScience @pnas.org

CREATE Medicines to Showcase Innovative CAR Therapy at J.P. Morgan Healthcare Conference CREATE Medicines will present groundbreaking updates in CAR therapy at the 44th Annual J.P. Morgan Healthcare Conference, highlighting significant clinical advancements.

CREATE Medicines to Showcase Innovative CAR Therapy at J.P. Morgan Healthcare Conference #United_States #San_Francisco #J.P._Morgan #CAR_therapy #CREATE_Medicines

Orna Therapeutics Showcases Promising In Vivo CAR Data at ASH Annual Meeting 2025 Orna Therapeutics shared compelling in vivo CAR program data targeting autoimmune diseases at the ASH Annual Meeting. Learn more about their innovative therapies.

Orna Therapeutics Showcases Promising In Vivo CAR Data at ASH Annual Meeting 2025 #USA #Watertown #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

Orna Therapeutics to Present Key Findings on CAR Programs at ASH Annual Meeting Orna Therapeutics announces significant presentations on its in vivo CAR therapies targeting autoimmune diseases at the upcoming ASH Annual Meeting in Orlando.

Orna Therapeutics to Present Key Findings on CAR Programs at ASH Annual Meeting #USA #Orlando #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

CREATE Medicines to Showcase Innovative MT-302 Data at SITC Annual Meeting CREATE Medicines is set to unveil pivotal clinical data on MT-302 during the SITC 40th Annual Meeting, highlighting groundbreaking CAR therapy for solid tumors.

CREATE Medicines to Showcase Innovative MT-302 Data at SITC Annual Meeting #USA #National_Harbor,_Maryland #CAR_therapy #CREATE_Medicines #MT-302

Orna Therapeutics to Showcase In Vivo CAR Therapy at ACR Annual Meeting Orna Therapeutics will highlight its innovative in vivo CAR therapy approach for autoimmune diseases at the upcoming ACR Annual Meeting in Chicago.

Orna Therapeutics to Showcase In Vivo CAR Therapy at ACR Annual Meeting #United_States #Chicago #Orna_Therapeutics #CAR_therapy #Autoimmune_Therapy

Ginkgo Bioworks Collaborates on Advanced CAR Therapy for Autoimmune Diseases Ginkgo Bioworks, in partnership with STRM.BIO and UBC, is advancing in vivo CAR therapies for autoimmune diseases under ARPA-H's EMBODY initiative.

Ginkgo Bioworks Collaborates on Advanced CAR Therapy for Autoimmune Diseases #USA #Boston #Ginkgo_Bioworks #CAR_therapy #STRM.BIO

Orna Therapeutics Unveils Promising Preclinical Results for CAR Therapy Targeting Autoimmune Disorders Orna Therapeutics has revealed groundbreaking preclinical data at the ASGCT Annual Meeting, showcasing its innovative in vivo CAR therapy aimed at autoimmune diseases, highlighting potent findings that could transform treatment.

Orna Therapeutics Unveils Promising Preclinical Results for CAR Therapy Targeting Autoimmune Disorders #United_States #New_Orleans #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

Next-Gen CAR T Therapy Breaks New Ground in Lymphoma Treatment Penn researchers unveil an enhanced CAR T-cell therapy that shows high remission rates in resistant lymphoma cases, with faster production and broader immune activation.

New CAR T-cell therapy achieves remission in over half of patients with resistant B-cell lymphomas, offering hope where previous treatments failed. #CAR_Therapy #LymphomaTreatment #CancerResearch

Orna Therapeutics to Showcase Innovative CAR Therapy for Autoimmunity at Major Conference Orna Therapeutics is set to present its cutting-edge in vivo CAR therapy for autoimmune conditions at the prestigious ASGCT Annual Meeting, exhibiting its groundbreaking approach in gene therapy.

Orna Therapeutics to Showcase Innovative CAR Therapy for Autoimmunity at Major Conference #United_States #New_Orleans #Orna_Therapeutics #Autoimmune_Diseases #CAR_therapy

FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T-Cell Therapy for Incurable Pediatric Brain Tumors BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today annou...

🔬 FDA grants Breakthrough Therapy status to @brainchildbio.bsky.social CAR T-cell therapy for DIPG, bringing real hope to families. Phase 2 trial set for late 2025.
🔗 tinyurl.com/4w972jss
#DIPG #PediatricCancer #CAR_Therapy

CAR-T therapy, a breakthrough cancer treatment, modifies a patient’s T-cells to target cancer. A study at Hadassah-University Medical Center in Jerusalem showed a 90% remission rate in 74 multiple myeloma patients, offering new hope for this previously incurable blood cancer. 🩷

#CAR_Therapy

Join our #CCBCancerLecture for an insightful talk by Hellen Ishikawa-Ankerhold on "Intravital microscopy: unlocking insights into tumor metastasis and CAR-T Cell Therapy."

📅 Tuesday January 28th
⌚ 13h
📍 Aula O&N5

#CancerResearch #CAR_Therapy #IntravitalMicroscopy